1. Home
  2. PMEC vs GBIO Comparison

PMEC vs GBIO Comparison

Compare PMEC & GBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Primech Holdings Ltd.

PMEC

Primech Holdings Ltd.

HOLD

Current Price

$1.07

Market Cap

40.0M

Sector

N/A

ML Signal

HOLD

Logo Generation Bio Co.

GBIO

Generation Bio Co.

HOLD

Current Price

$5.40

Market Cap

35.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PMEC
GBIO
Founded
1984
2016
Country
Singapore
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
40.0M
35.4M
IPO Year
2023
2020

Fundamental Metrics

Financial Performance
Metric
PMEC
GBIO
Price
$1.07
$5.40
Analyst Decision
Buy
Analyst Count
0
4
Target Price
N/A
$10.67
AVG Volume (30 Days)
188.8K
40.1K
Earning Date
01-01-0001
11-05-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$74,349,000.00
$15,270,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
2.52
N/A
52 Week Low
$0.54
$3.00
52 Week High
$2.44
$13.00

Technical Indicators

Market Signals
Indicator
PMEC
GBIO
Relative Strength Index (RSI) 44.66 49.94
Support Level $0.99 $5.22
Resistance Level $1.09 $5.64
Average True Range (ATR) 0.06 0.24
MACD 0.03 0.05
Stochastic Oscillator 63.64 55.93

Price Performance

Historical Comparison
PMEC
GBIO

About PMEC Primech Holdings Ltd.

Primech Holdings Ltd is a technology-driven facilities services provider in the public and private sectors operating mainly in Singapore. The services offered by the company include Facilities services, Stewarding services, Cleaning services to offices, Cleaning services to homes, and Cleaning Supplies.

About GBIO Generation Bio Co.

Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable differentiated therapeutic applications. Its first platform is a potent, selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.

Share on Social Networks: